Status:
COMPLETED
Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia
Lead Sponsor:
University of Cologne
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
PHASE3
Brief Summary
Over recent years an approach with the adjunctive administration of various anticonvulsant drugs has been discussed and a limited number of open and controlled studies were performed for carbamazepine...
Detailed Description
This is an explorative controlled study with Oxcarbazepine (OXC) as an adjunct in the acute treatment of schizophrenia. The study will be performed in subjects between 18 and 50 years of age with an a...
Eligibility Criteria
Inclusion
- Clinical diagnosis of schizophrenia or schizophreniform psychosis according to DSM-IV
- BPRS score \> 36 and BPRS psychosis cluster \> 12
- Ability to provide written informed consent
- Participants are required an adequate contraception
Exclusion
- Any severe neurological or somatic disorder
- Other psychiatric disorders including addictive disorders
- Positive urine drug screening for any compound except benzodiazepines
- No pregnancy or breast feeding
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT00637234
Start Date
July 1 2004
End Date
July 1 2008
Last Update
July 24 2008
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Isar-Amper-Klinikum gemeinnützige GmbH, Klinik Taufkirchen (Vils)
Taufkirchen (Vils), Bavaria, Germany, 84416
2
University of Cologne, Dept. of Psychiatry and Psychotherapy
Cologne, North Rhine-Westphalia, Germany, 50924